|Videos|March 30, 2023

Comparing Quadruplet Combination Treatment Regimens in NDMM

Author(s)Shaji Kumar, MD, Mayo Clinic, Sandy Wong, MD, Alexander Lesokhin, MD

The panel compares data between the three presented quadruplet combination regimens for NDMM, and which they would consider for older, frail patients.

Episodes in this series

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.

November 11th, 2026

Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.

European Commission Expands Melflufen Label to Third-Line Multiple Myeloma

November 10th, 2026

European Commission Expands Melflufen Label to Third-Line Multiple Myeloma

Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

November 4th, 2026

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

Trending on CancerNetwork

FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors

FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors

Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma

Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC

European Commission Expands Melflufen Label to Third-Line Multiple Myeloma